Hadley, Trevor D.
Agha, Ali M.
Ballantyne, Christie M.
Funding for this research was provided by:
National Institutes of Health (R01-HL134320)
Article History
Accepted: 11 February 2021
First Online: 1 April 2021
Compliance with Ethical Standards
:
: Trevor Hadley and Ali M. Agha have nothing to disclose. Christie M. Ballantyne has received grant/research support through his institution from Abbott Diagnostic, Akcea, Amgen, Esperion, Novartis, Regeneron, and Roche Diagnostic and is a consultant for Abbott Diagnostics, Akcea, Althera, Amarin, Amgen, Arrowhead, AstraZeneca, Corvidia, Denka Seiken, Esperion, Gilead, Janssen, Matinas BioPharma Inc, New Amsterdam, Novartis, Novo Nordisk, Pfizer, Regeneron, Roche Diagnostic and Sanofi-Synthelabo. He has received grant/research support through his institution from the National Institutes of Health, the American Heart Association, and the American Diabetes Association.
: This article does not contain any studies with human or animal subjects performed by any of the authors.